synthesis, antioxidant, and antidiabetic activities of (𝑍)-((dimethylcarbamothioyl) thio) ((1,1,1-trifluoro-4-oxo-4-phenylbut-2-en-2-yl) oxy) manganese hydrate

This study aimed to synthesize (z)-((dimethylcarbamothioyl) thio) ((1,1,1-trifluoro-4-oxo-4-phenylbut-2-en-2-yl) oxy) manganese hydrate (mnhcp) and investigate its antioxidant and antidiabetic activities via in vitro, ex vivo, and silico methods. mnhcp was synthesized via standard procedure. the complex was evaluated for its ability to scavenge free radicals, reduce ferric iron, and function as an iron chelator. oxidative pancreatic injury was induced by feso4 and treated with different concentrations of the complex. the inhibitory effect of the mnhcp on α-amylase and α-glucosidase enzymes was evaluated using metformin as standard. comparing mnhcp to quercetin (standard), the scavenging property rises significantly with concentration. the malondialdehyde, catalase, and entpdase activities, were reduced when the damaged pancreas was treated with mnhcp. in addition, following treatment with 1000 µg/ml of mnhcp, the pancreas had the greatest level of catalase, and higher levels of atpase and entpdase activities. mnhcp showed a dose-dependent inhibitory ability against α-amylase and α-glucosidase enzymes, compared with the standard drug (metformin). from the computational study, the stable binding and favourable dynamics pattern reflect that the test ligand molecule mnhcp could effectively inhibit the α-glucosidase and α-amylase functions in biological systems. therefore, this study showed that mnhcp effectively posed a significant antioxidant potential and inhibited α-amylase and α-glucosidase enzyme activity. thus, mnhcp could be seen as an alternative or lead antioxidant and antidiabetic drug, which can be utilized to produce nutraceuticals.